Antares Pharma has said that its Anturol gel met its primary endpoint of reduction in urinary incontinence episodes for both doses studied (56mg daily or 84mg daily) in a Phase 3 study evaluating patients with overactive bladder (OAB).
http://clinicaltrials.pharmaceutical-business-review.com/news/anturol_gel_met_phase_3_study_primary_endpoint_antares_pharma_100728/
How We Rank